Episode 196: The COSMIC-313 Trial Cabo/Ipi/Nivo in First-Line Renal Cancer

Toni Choueiri describes the phase 3 pivotal COSMIC-313 trial that evaluates the combination of cabozantinib with nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.